Amgen’s Targeted Cancer Drug Shows Early Promise in New Areas
- AMG-510 drives partial responses in advanced solid tumors
- Results could send shares of drug developer Mirati higher
This article is for subscribers only.
Amgen Inc.’s buzzed-about cancer treatment showed some promising signs that the experimental medicine might work in different tumor types.
In an early-stage study of 22 patients getting AMG 510 across a variety of cancers, three patients saw their tumors shrink and 13 didn’t have their cancer spread further while six showed signs of their disease progressing. The partial responders were patients with appendiceal and endometrial cancers and melanoma. The group didn’t include lung or colon cancer patients.